Carterra

Executive Summary

Carterra is a biotechnology company that has pioneered high-throughput surface plasmon resonance (SPR) platforms for antibody discovery and characterization. Its patented microfluidic technology and SPR imaging enable massively parallel screening of monoclonal antibodies, drastically reducing the time and cost of drug development. The company's flagship instruments, LSA and Vega, are used by leading pharmaceutical and biotech firms to accelerate the identification of high-quality therapeutic candidates. By integrating AI and machine learning, Carterra further enhances data analysis and predictive modeling, positioning itself at the intersection of biologics discovery and digital innovation. Carterra's technology addresses a critical bottleneck in antibody development, where conventional SPR methods are limited by low throughput. The company's platforms offer a compelling value proposition for large-scale screening and epitope binning, driving adoption among top-tier clients. With a strong IP portfolio and growing installed base, Carterra is well-placed to capitalize on the expanding biologics market. However, it faces competition from alternative high-throughput platforms and must continue to innovate to maintain its edge. Upcoming catalysts include the launch of next-generation instruments, expansion into AI-driven services, and potential strategic partnerships with major pharma companies.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation High-Throughput SPR Instrument70% success
• Q4 2026Strategic Partnership with Top 20 Pharma for Antibody Discovery50% success
• Q2 2026Integration of AI/ML Platform for Predictive Epitope Mapping60% success